Business ❯Pharmaceuticals
Drug Pricing Revenue Growth Drug Efficacy Pharmaceutical Industry Drug Development Liver Disease Mergers and Acquisitions Mergers and Acquisitions Corporate Finance Cost Savings
The deal, which could reach $2 billion with milestones, positions GSK to target unmet needs in liver disease with a planned 2029 launch.
